CATALYST PHARMACEUTICALS, INC. (CPRX): M&A transaction — Catalyst completes $160M acquisition of U.S. rights to FYCOMPA from Eisai, expects accretion in 2023

CATALYST PHARMACEUTICALS, INC.

Paid $160M upfront all-cash to Eisai; potential milestone/royalty payments under certain conditions.
FYCOMPA net revenue for FY ending March 31, 2023 expected ~$136M; gross margin similar to FIRDAPSE.
Eisai will supply FYCOMPA for 7 years and provide transition services for up to 180 days post-closing.
Acquisition expected to be accretive to EBITDA and EPS in 2023; FIRDAPSE revenue guidance unchanged at $205-210M.
Overlaps ~45% with FIRDAPSE physician call points; strengthens neuroscience portfolio.

item 2.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

CATALYST PHARMACEUTICALS, INC. completed an acquisition involving Eisai Co., Ltd. for $160 million (closed 2023-01-24).

Action: acquisition
Counterparty: Eisai Co., Ltd.
Consideration: $160 million
Closing: 2023-01-24

Exact text from the filing

Asset Purchase Agreement (the “ Purchase Agreement ”) between the Company and Eisai. Under the terms of the Purchase Agreement, the Company paid an upfront payment to Eisai of $160 million. Also at the closing of the asset purchase, the parties entered into two related agreements: (i) a short term Transition Services Agreement (the “ Transition Services Agreement

View on SEC.gov

68 m&a transactions filed in the last 30 days. Browse all m&a transactions →

CATALYST PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-019083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.